Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.63 |
---|---|
High | 18.63 |
Low | 18.63 |
Bid | 18.86 |
Offer | 18.95 |
Previous close | 17.87 |
Average volume | 177.89 |
---|---|
Shares outstanding | 124.32m |
Free float | 118.76m |
P/E (TTM) | -- |
Market cap | 2.58bn USD |
EPS (TTM) | -4.65 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 07:08 BST.
More ▼
Press releases
- Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
- Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
- Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
- Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
- Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
- Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
More ▼